Onward Therapeutics is a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer.
Our company, led by an experienced team in translational science and drug development, acquires licenses for potential development can
Our company, led by an experienced team in translational science and drug development, acquires licenses for potential development can
Mentions in press and media 7
| Date | Title | Description |
| 23.04.2025 | A New Dawn in Cancer Treatment: Onward Therapeutics' Bold Move with NK Cell Therapy | In the world of biotechnology, breakthroughs often feel like whispers in a storm. Yet, some announcements resonate like thunder. Onward Therapeutics has just made such a declaration. The company, rooted in Switzerland, is stepping into the ... |
| 23.04.2025 | Swiss biotechs on track to address key medical challenges | Onward Therapeutics SA is focused on advancing innovative cancer immunotherapies through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex, alongside an equity investment; and an ... |
| 22.04.2025 | Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab | EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ -- Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has received Investigati... |
| 24.01.2024 | Onward Therapeutics transitions to the clinical stage | Onward Therapeutics licensed the exclusive worldwide rights of development, manufacture, and commercialization of OT-A201 from Biomunex Pharmaceuticals (Biomunex), a biopharmaceutical company discovering and developing bi- and multi-specif... |
| 24.01.2024 | Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints | EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the pha... |
| 27.11.2023 | Sparks IPO Academy prepares new cohort for next move | |
| 08.06.2021 | Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier | EPALINGES, Switzerland, June 8, 2021 /PRNewswire/ -- Onward Therapeutics (Onward) and Institut du Cancer de Montpellier (ICM) announced today the execution of an exclusive collaboration and worldwide option and license agreement based on a ... |